BlackRock Portfolio Management LLC filed an amended Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 8,219,061 shares of Myriad Genetics Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock Portfolio Management LLC reported beneficial ownership of 8,219,061 shares of Myriad Genetics Inc common stock.
  • Percent of class: The reported stake represents 8.6% of the outstanding common shares, according to the filing.
  • Sole voting power: The filing discloses sole voting power over 7,270,669 shares.
  • Sole dispositive power: BlackRock Portfolio Management LLC reported sole dispositive power over all 8,219,061 shares.
  • No shared voting or dispositive power: Both shared voting power and shared dispositive power are listed as 0 shares.
  • Event date: The date of the event requiring this filing is listed as September 30, 2026.
  • Filer classification: The reporting person is classified as a holding company (type HC), organized in Delaware.

BlackRock Portfolio Management's Amended 13G Position in Myriad Genetics

BlackRock Portfolio Management LLC, headquartered at 50 Hudson Yards, New York, NY 10001, submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Myriad Genetics Inc (NASDAQ:MYGN), whose principal executive offices are located at 322 North 2200 West, Salt Lake City, UT 84116. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, with a triggering event date of September 30, 2026.

According to the filing, the aggregate amount beneficially owned by BlackRock Portfolio Management LLC is 8,219,061 shares of common stock (CUSIP 62855J104), equal to 8.6% of the class. Of those shares, the filer reported sole voting power over 7,270,669 shares and sole dispositive power over the full 8,219,061 shares. Shared voting and shared dispositive power are each reported as zero.

The filing states that, in accordance with SEC Release No. 34-39538 dated January 12, 1998, this Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates." The filing further discloses that various persons have the right to receive dividends or proceeds from the sale of the common stock, but notes that "no one person's interest in the common stock of MYRIAD GENETICS INC is more than five percent of the total outstanding common shares." The filing certifies the securities were acquired and held in the ordinary course of business.

What Was Disclosed

BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting beneficial ownership of 8,219,061 shares, or 8.6%, of Myriad Genetics Inc common stock as of September 30, 2026, with sole voting power covering 7,270,669 of those shares.